New Biotech Offering Targets $426B Rare Disease Market
The rare disease drug space is growing fast-and so is investor interest. With exclusivity, pricing power and major M&A moves, the rare disease space is getting interesting. This company has the science and the experience.
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and consistent safety profiles.
Amazon spends $1 billion to increase pay and lower health care costs for US workers
NEW YORK (AP) — Amazon says it's making a $1 billion investment to raise wages and lower the cost of health care plans for its U.S. fulfillment and transportation workers.
Want To Know the No.1 Crypto and the No.1 Stock? - Ad
The #1 crypto is just $3. Crypto analysts say a cash injection could drive it as high as $100 in the next year. The #1 stock is equally exciting. It's less than $10 but made a HUGE deal recently to work with Nvidia.
Mini-meditations are a way to foster peace of mind at work
NEW YORK (AP) — The idea of meditating can be intimidating. Beginners may imagine sitting uncomfortably in silence while and scrubbing all thoughts from their minds. The prospect of trying those techniques at work may feel embarrassing.
After accomplishments in politics, media, former CNN chief Tom Johnson makes mental health his cause
NEW YORK (AP) — Tom Johnson's career took him from the White House to newspaper publisher jobs in Dallas and Los Angeles to president of CNN. While that left him able to swap stories about two influential figures — Lyndon B. Johnson and Ted Turner — that's not the real reason he wrote his memoir.
Why This Crypto Skeptic Had a Change of Heart - Ad
He used to make fun of crypto. Now... he says one $3 crypto could rise to $92 by next year.
Democrats embrace a shutdown fight in a rare moment of unity against Trump
NEW YORK (AP) — On this, at least, the Democrats agree: It's time to fight.
Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer
Nanobiotix reported updated Phase 1 trial data for JNJ-1900 in head and neck cancer, showing strong disease control and survival outcomes.
Time to Say Goodbye to "Old" Dollar? Say Hello to "Trump's New Dollar" - Ad
If you have any money in U.S. dollars... learn how to prepare for "Trump's new dollar"... Because this could be the biggest change to our financial system in 54 years. President Trump even called it: "The greatest revolution in financial technology since the birth of the internet itself."
What will happen if there's a government shutdown at day's end
WASHINGTON (AP) — Washington is hours away from another , with prospects looking bleak for a last-minute compromise in Congress to avoid closures beginning at 12:01 a.m. Wednesday.
Medicare Beneficiaries To See Slight Premium Decline Next Year
CMS projects stable Medicare Advantage and Part D premiums in 2026, with new tools to help beneficiaries compare plans during Open Enrollment.
Biotech With Multiple Orphan Drugs Is Quietly Opening Its Doors - Ad
A promising biotech developing treatments for rare childhood brain diseases is opening a new raise. Its lead drug has fast-track status, orphan designations, is nearing Phase 2 and backed by a Global Integrator.
CEO of drugmaker GSK to step down by year's end
LONDON (AP) — GSK Chief Executive Emma Walmsley, the first woman to lead a major pharmaceutical company, will step down Dec. 31 after more than eight years at the head of the London-based drugmaker.
Albertsons recalls several deli items due to potential listeria contamination
NEW YORK (AP) — Albertsons Companies has recalled several of its store-made deli products because they may contain listeria bacteria, in a move that arrives shortly after federal health officials certain pasta meals sold at Walmart and Trader Joe’s over similar contamination concerns.
The "Mar-A-Lago Accord" Is Now Underway - Ad
The global order is in chaos. And according to 40-year market veteran Dr. David Eifrig, the biggest controlled demolition of the old monetary order in history could now be here, too. That means if you don't take action today, your wealth could decline by 40%... (Yes, even your cash savings.)
Sanofi Expands Insulin Savings Program To Cover All US Patients
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: SNY) Genzyme Corporation.
FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder
On Thursday, the U.S.
New Biotech Offering Targets $426B Rare Disease Market - Ad
The rare disease drug space is growing fast-and so is investor interest. With exclusivity, pricing power and major M&A moves, the rare disease space is getting interesting. This company has the science and the experience.
Woman sues Universal Orlando over injuries from same roller coaster in which man died after ride
ORLANDO, Fla. (AP) — A woman has sued Universal Orlando Resort, claiming she was injured on a roller coaster at its newest theme park. The lawsuit, filed Wednesday, comes a week from blunt impact injuries after going on the same ride.
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with
Elon's $25 Trillion Confession - Ad
Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.
Bill Clinton sees this year's Clinton Global Initiative as a 'counterweight' to aid cuts
NEW YORK (AP) — Former President Bill Clinton opened the annual meeting of the Clinton Global Initiative Wednesday with a list of things that worry him.
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies
A judge upholds Maine's contract pharmacy law, rejecting drugmakers' claims that it conflicts with federal rules governing the 340B drug discount program.
Rare Disease Biotech Offers Access Ahead of Key Milestone - Ad
This late-stage biotech is gearing up for Phase 2 trials with an FDA-designated orphan drug. It's already drawing comparisons to recent billion-dollar exits. Backed by a proven biotech incubator, it's now offering early access to its raise.
Al Gore's satellite and AI system is now tracking sources of deadly soot pollution
NEW YORK (AP) — Soon people will be able to use satellite technology and artificial intelligence to track dangerous soot pollution in their neighborhoods — and where it comes from — in a way not so different from monitoring approaching storms under plans by a nonprofit coalition led by former Vice President Al Gore.
3 Tricky Decisions for Every Retirement Plan
Retirement planning is complicated.
How the Multiplier Effect is Working on This $3 Crypto - Ad
It's called the multiplier effect in crypto. In short, because of a lack of supply, small inflows of cash can create major moves in the overall value of the crypto. And it's particularly strong in one $3 crypto. Crypto analysts are suggesting it could rise to as high as $100 by next year.
More shrimp sold at Kroger stores recalled for possible radioactive contamination
A Seattle seafood distributor more cooked and frozen shrimp sold at Kroger grocery stores across the U.S. because of ongoing concerns about potential radioactive contamination.
Aetna Expands Hospital Program To Cut Readmissions
Aetna, a CVS Health unit, is expanding its Clinical Collaboration program to 10 hospitals to cut readmissions.
The Tesla Shock Nobody Sees Coming - Ad
While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
A robot programmed to act like a 7-year-old girl works to combat fear and loneliness in hospitals
Days after Meagan Brazil-Sheehan’s 6-year-old son was diagnosed with leukemia, they were walking down the halls of UMass Memorial Children’s Medical Center when they ran into Robin the Robot.
Organic food prices could soar as US imposes import restrictions and new tariffs on specialty sugar
SIOUX FALLS, S.D. (AP) — The price of most organic food could jump this fall due to new policies and tariffs on imported organic sugar, frustrating manufacturers who say the actions won't help sugar growers but could put some food companies out of business.
Want To Know the No.1 Crypto and the No.1 Stock? - Ad
The #1 crypto is just $3. Crypto analysts say a cash injection could drive it as high as $100 in the next year. The #1 stock is equally exciting. It's less than $10 but made a HUGE deal recently to work with Nvidia.
UN report cites huge government corruption in South Sudan as its food crisis worsens
NAIROBI, Kenya (AP) — Billions of dollars in public funds in South Sudan have been stolen over the past decade in massive government corruption while the vast majority of the country suffers food insecurity, a U.N. commission said Tuesday.
Why This Crypto Skeptic Had a Change of Heart - Ad
He used to make fun of crypto. Now... he says one $3 crypto could rise to $92 by next year.
Here's Novo Nordisk's First Oral Obesity Drug In Europe With Proven Heart Health Impact
EMA approved Rybelsus' label update after the SOUL trial showed it cuts heart attack, stroke, and death by 14% in high-risk type 2 diabetes patients.
Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks
FDA Commissioner Martin Makary said Hims & Hers broke federal law with its Super Bowl ad promoting weight-loss drugs without disclosing side effects, and called it "the most overt breach" of FDA rules.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.